These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19334421)

  • 1. [Activity indices--objective criteria of the estimation of severity level of ulcerous colitis].
    Bakulin IG; Stanke DA; Belousova EA; Golovenko OV; Mikhailova TL
    Eksp Klin Gastroenterol; 2008; (6):14-6. PubMed ID: 19334421
    [No Abstract]   [Full Text] [Related]  

  • 2. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment.
    Bresci G; Parisi G; Capria A
    Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature].
    Neĭman KP; Rumiantsev VG
    Eksp Klin Gastroenterol; 2006; (3):56-60. PubMed ID: 17203844
    [No Abstract]   [Full Text] [Related]  

  • 5. Salmonellosis and ulcerative colitis. A causal relationship or just a coincidence.
    Karaoglu AO; Yukselen V; Ertem GT; Erkus M
    Saudi Med J; 2004 Oct; 25(10):1486-8. PubMed ID: 15494829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive colonic mucosal defect induced by mesalamine.
    Kato J; Yoshida T; Kitano M
    Dig Endosc; 2018 May; 30(3):390-391. PubMed ID: 29469941
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
    Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rational approach to 5-aminosalicylic acid therapy in ulcerative colitis.
    Miner PB; Peppercorn MA; Targan SR
    Hosp Pract (Off Ed); 1993 Dec; 28 Suppl 3():1-24. PubMed ID: 8270648
    [No Abstract]   [Full Text] [Related]  

  • 11. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?
    Higgins PD; Schwartz M; Mapili J; Zimmermann EM
    Am J Gastroenterol; 2005 Feb; 100(2):355-61. PubMed ID: 15667493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ulcerative colitis. Evaluation of a newly developed activity index within the scope of a therapeutic study of mesalazin].
    Maier K; von Gaisberg U; Kraus B; Kimmig JM; Tippmann P; Gerhard F; Lepiorz P
    Fortschr Med; 1987 Jan; 105(2):61, 65-6, 69. PubMed ID: 3557255
    [No Abstract]   [Full Text] [Related]  

  • 13. 37-year-old man with abdominal pain.
    Snipelisky DF; Cable CA; Maniaci MJ
    Mayo Clin Proc; 2014 Apr; 89(4):558-62. PubMed ID: 24684877
    [No Abstract]   [Full Text] [Related]  

  • 14. "One more time" 5-ASA retrial after a glucocorticosteroid induced remission in moderate to severe ulcerative colitis: a prospective community practice experience.
    Lipka S; Katz S; Kaur N
    J Crohns Colitis; 2013 May; 7(4):342-3. PubMed ID: 22871515
    [No Abstract]   [Full Text] [Related]  

  • 15. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinicomorphological characterization of segmental lesion in ulcerous colitis].
    Vorob'ev GI; Khalif IL; Malakhova NS; Kapuller LL; Vasil'chenko AV; Mikhaĭlova TL; Golovenko OV
    Klin Med (Mosk); 2007; 85(1):44-7. PubMed ID: 17419355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ulcerative colitis and thrombocytopenia: a clinical case of fortuitous association?].
    Braucci S; Trappolini F; Angrisani L; Luberti E; Clarice A; Proietta M; Pisani D; Trappolini M
    Clin Ter; 2007; 158(1):27-30. PubMed ID: 17405657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease.
    Siegel CA
    Gastroenterology; 2009 Dec; 137(6):1880-2. PubMed ID: 19879213
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation and analysis of colonoscopy in the diagnosis of 186 cases of ulcerative colitis patients.
    Ding YJ; Yu JP; Luo HS; Zhou ZY; Liu J
    Int J Clin Pract; 2006 Nov; 60(11):1408-10. PubMed ID: 16669833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Colitis ulcerosa - a diagnostic and therapeutic update].
    Fischer S; Neurath MF; Atreya R
    MMW Fortschr Med; 2016 Apr; 158(8):77-80. PubMed ID: 27116171
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.